Enhanced mucosal B- and T-cell responses against SARS-CoV-2 after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant.
Gabriel Laghlali, Matthew J. Wiest, Dilara Karadağ, Prajakta Warang, Jessica J. O’Konek, Lauren A. Chang, Seok‐Chan Park, Vivian Yan, Mohammad Farazuddin, Katarzyna W. Janczak, Adolfo García‐Sastre, James R. Baker, Pamela T. Wong, Michael Schotsaert
This study shows that combining intramuscular mRNA priming with intranasal protein boosting using a combination adjuvant enhances mucosal B- and T-cell responses against SARS-CoV-2 compared to other vaccination regimens.
Molecular Therapy · Oct 30, 2024Peer-reviewedImmunology